Simon Dearden

3.5k total citations · 3 hit papers
30 papers, 2.6k citations indexed

About

Simon Dearden is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Simon Dearden has authored 30 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 17 papers in Cancer Research and 16 papers in Oncology. Recurrent topics in Simon Dearden's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (16 papers) and PARP inhibition in cancer therapy (8 papers). Simon Dearden is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (16 papers) and PARP inhibition in cancer therapy (8 papers). Simon Dearden collaborates with scholars based in United Kingdom, United States and Canada. Simon Dearden's co-authors include Rose McCormack, Anita Midha, Yi‐Long Wu, David P. Blowers, James Stevens, Mireille Cantarini, Suzanne Jenkins, J. Carl Barrett, Kenneth S. Thress and Helen Brown and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Simon Dearden

30 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

2015 655 citations Simon Dearden, Rose McCormack et al. profile →
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

2013 491 citations Simon Dearden, James Stevens et al. Annals of Oncology profile →
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

2015 401 citations Kenneth S. Thress, Roz Brant et al. Lung Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Dearden United Kingdom	16	2.0k	1.4k	1.2k	761	258	30	2.6k
Teresa Morán Spain	26	1.9k 0.9×	1.6k 1.1×	627 0.5×	1.0k 1.4×	177 0.7×	130	2.7k
Viola W. Zhu United States	30	2.1k 1.1×	1.7k 1.2×	646 0.5×	1.0k 1.3×	283 1.1×	83	2.6k
Hannah Stubbs United States	8	2.1k 1.0×	1.8k 1.3×	675 0.5×	1.1k 1.5×	353 1.4×	9	2.9k
Michèle Beau‐Faller France	22	1.6k 0.8×	1.3k 0.9×	554 0.5×	758 1.0×	156 0.6×	61	2.1k
Roberta Minari Italy	25	1.7k 0.8×	1.5k 1.0×	585 0.5×	1.1k 1.5×	208 0.8×	66	2.5k
Haichuan Hu China	28	2.3k 1.1×	1.6k 1.1×	743 0.6×	1.0k 1.4×	223 0.9×	48	2.9k
Rose McCormack United Kingdom	11	1.7k 0.8×	1.1k 0.7×	1.1k 0.9×	444 0.6×	207 0.8×	11	2.0k
Yuri Rukazenkov United Kingdom	21	3.7k 1.8×	3.0k 2.1×	945 0.8×	1.0k 1.3×	171 0.7×	55	4.1k
Mafalda Oliveira Spain	24	1.1k 0.5×	1.5k 1.0×	893 0.7×	680 0.9×	187 0.7×	172	2.2k
Felice Mucilli Italy	16	1.5k 0.7×	1.1k 0.8×	464 0.4×	756 1.0×	139 0.5×	59	2.0k

Countries citing papers authored by Simon Dearden

Since Specialization

Citations

This map shows the geographic impact of Simon Dearden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Dearden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Dearden more than expected).

Fields of papers citing papers by Simon Dearden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Dearden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Dearden. The network helps show where Simon Dearden may publish in the future.

Co-authorship network of co-authors of Simon Dearden

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Dearden. A scholar is included among the top collaborators of Simon Dearden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Dearden. Simon Dearden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jones, Melanie A., Kirsten M. Timms, Elizabeth S. Cogan, et al.. (2023). The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing. Genes Chromosomes and Cancer. 62(10). 589–596. 3 indexed citations

N., Kim, Alan Barnicle, Zhongwu Lai, et al.. (2022). Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research. 29(1). 81–91. 46 indexed citations

Li, Bob T., Myung‐Ju Ahn, Kōichi Goto, et al.. (2022). Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).. Journal of Clinical Oncology. 40(16_suppl). TPS9137–TPS9137. 9 indexed citations

Hodgson, Darren, Zhongwu Lai, Simon Dearden, et al.. (2021). Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Annals of Oncology. 32(12). 1582–1589. 26 indexed citations

Hodgson, Darren, Jessica Brown, Simon Dearden, et al.. (2021). Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. Gynecologic Oncology. 163(3). 563–568. 10 indexed citations

Matsubara, Nobuaki, Johann S. de Bono, David Olmos, et al.. (2021). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. Journal of Clinical Oncology. 39(6_suppl). 27–27. 15 indexed citations

Veeramachaneni, Ratna, Timothée Revil, Antoine de Weck, et al.. (2019). Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy. Scientific Reports. 9(1). 11992–11992. 34 indexed citations

Akamatsu, Hiroaki, Angelo Delmonte, Thomas John, et al.. (2017). EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. x128–x128. 5 indexed citations

Jenkins, Suzanne, James Chih‐Hsin Yang, Pasi A. Jänne, et al.. (2017). EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Journal of Thoracic Oncology. 12(8). 1247–1256. 46 indexed citations

10.

Dearden, Simon, Helen Brown, Suzanne Jenkins, et al.. (2017). EGFR T790M mutation testing within the osimertinib AURA Phase I study. Lung Cancer. 109. 9–13. 20 indexed citations

11.

Sherwood, James, Simon Dearden, M. Ratcliffe, & Jill Walker. (2015). Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. Journal of Experimental & Clinical Cancer Research. 34(1). 92–92. 49 indexed citations

12.

Thress, Kenneth S., Roz Brant, T. Hedley Carr, et al.. (2015). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 90(3). 509–515. 401 indexed citations breakdown →

13.

Douillard, Jean‐Yves, Gyula Ostoros, Manuel Cobo, et al.. (2014). Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology. 9(9). 1345–1353. 348 indexed citations

14.

Thress, Kenneth S., Roz Brant, T. Hedley Carr, et al.. (2014). EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.. Journal of Clinical Oncology. 32(15_suppl). 8092–8092. 6 indexed citations

15.

Cumberbatch, Marie, Ximing Tang, Garry Beran, et al.. (2013). Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma. Clinical Cancer Research. 20(3). 595–603. 22 indexed citations

16.

Dearden, Simon, Chris Harbron, Darren Hodgson, et al.. (2013). Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 462(3). 269–279. 20 indexed citations

17.

Dearden, Simon, James Stevens, Yi‐Long Wu, & David P. Blowers. (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology. 24(9). 2371–2376. 491 indexed citations breakdown →

18.

Smith, John, Laura Brooks, Paulo M. Hoff, et al.. (2013). KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer. 49(10). 2424–2432. 14 indexed citations

19.

Ellison, Gillian, et al.. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology. 66(2). 79–89. 235 indexed citations

20.

Board, Ruth, Gillian Ellison, Maria Orr, et al.. (2009). Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. British Journal of Cancer. 101(10). 1724–1730. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact